NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Both Staffing 360 Solutions and IsoRay were two of the biggest winners in Monday’s trading session with gains of about 300% and 143% respectively. Both soared on positive developments.
RDI Initiates Coverage on:
Staffing 360 Solutions, Inc.
Staffing 360 Solutions, Inc. shares exploded in Monday trading, closing the day up a staggering 301.46% on tremendous volume. The staffing company had some big news announcing that it has entered the Resource Process Outsourcing market with the acquisition of Clement May Limited, which provides IT recruitment services. Clement May made $50 million in revenues in the trailing 12 months that ended in June 2018. CEO of Staffing 360 Solutions, Brendan Flood, commented, "The acquisition of Clement May reflects our continuing focus on strategic M&A activity that, in concert with an intelligent integration program, is designed to drive top line growth towards our stated revenue goal of $500 million over the next two years and bring us one step closer to generating positive net income." He added, "While our operations in the US have the ability to deliver on volume projects, we were limited in the UK in this regard. This acquisition allows us to deliver additional quality and service to our client base, strengthens our position in the IT staffing market and allows for more international cross-selling within the group."
Access RDI's Staffing 360 Solutions, Inc. Research Report at:
IsoRay, Inc. shares skyrocketed on Monday to close the day up 143.18% on explosive volume compared to usual. The stock traded nearly 34 million shares versus an average trading volume of just around 244,000 shares. Shares also hit a brand new high of $1.22 during intra-day trading after the medical technology company said it entered into definitive agreements with several institutional investors for the purchase in a registered direct offering of 11,000,000 shares of its common stock, at a purchase price of $0.75 per share, for gross proceeds of $8.25 million. Additionally, IsoRay has also agreed to issue to the investors unregistered warrants to purchase up to 5,500,000 shares of common stock. The company, which is an innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, said it plans to use the net proceeds from this offering for working capital and general corporate purposes with particular focus on marketing the brain applications and Build-Blu™ delivery system for real-time prostate brachytherapy.
Access RDI's IsoRay, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.